Nabilone controlled release - AOP Orphan Pharmaceuticals

Drug Profile

Nabilone controlled release - AOP Orphan Pharmaceuticals

Alternative Names: Nabilone FDT

Latest Information Update: 20 Sep 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator AOP Orphan Pharmaceuticals AG
  • Developer AOP Orphan Pharmaceuticals AG; Innsbruck Medical University
  • Class Antiemetics; Cannabinoids; Non-opioid analgesics; Small molecules
  • Mechanism of Action Cannabinoid receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Phase II Pain; Parkinson's disease

Most Recent Events

  • 15 Sep 2017 Phase-II clinical trials in Parkinson's disease (In adults, In the elderly, Second-line therapy or greater) in Austria (PO) (EudraCT2017-000192-86)
  • 10 Jun 2016 Orthopädisches Spital Speising GmbH and AOP Orphan Pharmaceuticals initiate the pilot phase II Cannabinoid-Spinal-Fusion-Study trial for Pain in Austria (PO, Capsule) (EudraCT2015-004227-31)
  • 01 Mar 2016 Phase-II development is ongoing in Austria (PO)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top